Sep. 14 at 8:32 PM
$BNTC - Benitec Biopharma Inc - 10K - Updated Risk Factors
BNTC flags continued heavy losses, no product revenue, dependence on new capital to remain a going concern, early-stage unproven ddRNAi gene therapy facing tougher FDA demands and trial hurdles, heavy reliance on third parties and IP protection, uncertain physician/payer uptake, and added risks from U.S. government funding and FDA staffing disruptions. #Biopharmaceuticals #GeneTherapy #RegulatoryRisk #CapitalDependency #IntellectualProperty
🟢 Added 🟠Removed
https://d-risk.ai/BNTC/10-K/2026-09-14
